Jennison Associates LLC Trims Stake in Prestige Consumer Healthcare Inc. $PBH

Jennison Associates LLC decreased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 16.9% during the fourth quarter, Holdings Channel reports. The fund owned 209,677 shares of the company’s stock after selling 42,539 shares during the period. Jennison Associates LLC’s holdings in Prestige Consumer Healthcare were worth $12,935,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Torren Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $35,000. M&T Bank Corp boosted its position in shares of Prestige Consumer Healthcare by 66.4% in the 4th quarter. M&T Bank Corp now owns 6,245 shares of the company’s stock worth $386,000 after purchasing an additional 2,492 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in shares of Prestige Consumer Healthcare by 11.2% in the 4th quarter. Pictet Asset Management Holding SA now owns 8,386 shares of the company’s stock worth $517,000 after purchasing an additional 842 shares in the last quarter. UBS Group AG boosted its position in shares of Prestige Consumer Healthcare by 0.9% in the 4th quarter. UBS Group AG now owns 424,230 shares of the company’s stock worth $26,171,000 after purchasing an additional 3,765 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its position in shares of Prestige Consumer Healthcare by 18.2% in the 4th quarter. Impax Asset Management Group plc now owns 130,000 shares of the company’s stock worth $8,020,000 after purchasing an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on PBH. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Jefferies Financial Group dropped their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $76.50.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $54.98 on Friday. The firm has a market cap of $2.60 billion, a PE ratio of 14.55, a P/E/G ratio of 1.65 and a beta of 0.40. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The firm has a fifty day simple moving average of $61.10 and a two-hundred day simple moving average of $62.06. Prestige Consumer Healthcare Inc. has a 1-year low of $51.24 and a 1-year high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The company had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. Prestige Consumer Healthcare’s quarterly revenue was down 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.54 EPS for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares in the company, valued at approximately $2,706,294.64. The trade was a 2.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).